Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ chronic myeloid leukemia patients treated with imatinib mesylate

G. Fugazza, M. Miglino, R. Bruzzone, S. Quintino, A. M. Gatti, R. Grasso, M. Gobbi, F. Frassoni, Mario Sessarego

Research output: Contribution to journalArticle

Abstract

Imatinib mesylate determines a favorable clinical course in most Ph positive Chronic Myeloid Leukemia (CML) patients in the chronic phase. Cytogenetic response is usually evaluated by analyzing 20-25 bone marrow metaphases using standard banding techniques. Since this methodology has very low sensitivity, we compared the results obtained by standard banding techniques to the ones obtained by fluorescent in situ hybridization (FISH). This was also done to identify any possible discrepancies between the two techniques. We analyzed 40 Ph+ CML patients in the chronic phase who had previously been treated with interferon alpha (IFNα) and who were receiving imatinib. The studies were performed by utilizing the same BM cell samples fixed in acetic acid/methanol, before imatinib therapy and then quarterly. Comparison of cytogenetic results to FISH results at 3 and 6 months of imatinib treatment showed that some patients who had achieved major cytogenetic response (i.e.

Original languageEnglish
Pages (from-to)295-299
Number of pages5
JournalJournal of Experimental and Clinical Cancer Research
Volume23
Issue number2
Publication statusPublished - Jun 2004

Keywords

  • Chromosome Philadelphia
  • Chronic myeloid leukemia
  • Fluorescent in situ hybridization
  • Imatinib therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ chronic myeloid leukemia patients treated with imatinib mesylate'. Together they form a unique fingerprint.

  • Cite this